Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma

Business Wire September 6, 2016

Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13

Business Wire August 31, 2016

Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress

Business Wire August 31, 2016

Kinder Morgan trade offers a 6% return in 108 days, or find similar option trades on Amazon.com, Alleghany Technologies, Boeing, and Exelixis

PR Newswire August 30, 2016

Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019

Business Wire August 24, 2016

Research Report on Biotech Equities -- Gilead Sciences, Exelixis, Ariad Pharma, and Novavax

PR Newswire August 19, 2016

Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you choose

PR Newswire August 15, 2016

Watch These 7 Huge Put Purchases In Friday Trade

Benzinga.com  August 5, 2016

Major Averages Close Thursday's Session Mostly Unchanged

Benzinga.com  August 4, 2016

Stocks Hitting 52-Week Highs

Benzinga.com  August 4, 2016

Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update

Business Wire August 3, 2016

Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016

Business Wire July 12, 2016

9 Biggest Mid-Day Gainers For Monday

Benzinga.com  June 6, 2016

Stocks Hitting 52-Week Highs

Benzinga.com  June 6, 2016

10 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  June 6, 2016

Exelixis et son partenaire Ipsen présentent les résultats positifs de survie globale issus de l'analyse des sous-groupes de l'essai de phase 3 avec CABOMETYX™ (comprimés de cabozantinib), lors de la réunion annuelle 2016 de l'ASCO

Business Wire June 6, 2016

Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting

Business Wire June 6, 2016

Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO

Business Wire June 5, 2016

Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

Business Wire June 5, 2016

Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma

Business Wire May 23, 2016